C
CG Oncology
Focused on developing bladder cancer therapeutics
About CG Oncology
CG Oncology is a late-stage biopharmaceutical company developing bladder-sparing immunotherapies for patients with urologic cancers. Its lead candidate, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy delivered directly into the bladder (intravesically) for non-muscle invasive bladder cancer (NMIBC). The company was formerly known as Cold Genesys.
Cretostimogene holds FDA Fast Track and Breakthrough Therapy designations. In the pivotal Phase 3 BOND-003 trial (Cohort C) in high-risk NMIBC that no longer responds to standard BCG treatment, it showed a 41.8% complete response rate at 24 months. The results were published in The Lancet Oncology in July 2026. The company has begun a rolling Biologics License Application (BLA) to the FDA for this indication and expects to complete it in Q4 2026. A Phase 3 trial in intermediate-risk NMIBC, PIVOT-006, has topline results expected soon, and the Phase 2 CORE-008 trial is evaluating patients previously treated with BCG.
CG Oncology went public on Nasdaq (CGON) in January 2024, raising $380M, and is headquartered in Dallas, Texas. Cretostimogene is investigational and not yet approved by any regulatory agency.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2024
Open roles
CG Oncology in the Dallas ecosystem
The CG Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Ally Bridge Group
WI Harper Group
Series B and later16 investors entered at this stage
Perseverance Capital Management- AFAsian Healthcare Fund
ORI Capital- KPKissei Pharmaceutical
Camford Capital
RA Capital Management
Longitude Capital
Decheng Capital- SCSirona Capital
Malin Corporation
Acorn Bioventures
BVF Partners
Foresite CapitalJanus Henderson Investors
TCGX
Avidity Partners
Source: Dealroom Talent Intelligence.
Global footprint
Patents
2 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See CG Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
CG Oncology's cretostimogene cuts bladder cancer recurrence risk by 68% in Phase 3 PIVOT-006
CG Oncology publishes Phase 3 BOND-003 Cohort C results for cretostimogene in The Lancet Oncology

